SOLENO THERAPEUTICS INC SLNO Balance Sheet

Soleno therapeutics inc (SLNO)

Balance Sheet / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Dec'13
Assets
Current assets
Cash and cash equivalents
15,070	20,733	11,225	15,503	19,402	23,099	10,239	12,593	14,866	17,100	5,647	7,547	10,539	2,725	5,415	2,502	6,492	5,494	4,720	7,530	9,529	7,956	1,268
Accounts receivable
-	-	-	-	-	-	-	-	-	-	0	3	110	-	137	288	187	-	94	12	8	0	149
Restricted cash
-	-	-	-	-	-	-	-	35	35	35	35	35	35	35	35	35	35	111	35	20	20	20
Inventory
-	-	-	-	-	-	-	-	-	-	-	164	855	-	703	774	653	-	376	277	206	109	-
Prepaid expenses and other current assets
572	411	375	471	603	529	327	248	423	343	145	246	261	246	217	157	216	159	225	311	260	252	85
Due from related party
-	-	9	18	72	64	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Minority interest investment in former subsidiary
-	-	-	623	788	978	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Current assets held for sale
-	-	-	-	-	-	847	470	484	516	563	2,323	-	793	-	-	-	715	-	-	-	-	-
Total current assets
15,642	21,144	11,609	16,615	20,865	24,670	11,413	13,311	15,808	17,994	6,390	10,318	11,800	3,801	6,507	3,756	7,583	6,404	5,526	8,165	10,023	8,338	1,523
Long-term assets
Property and equipment, net
19	22	46	22	19	12	14	13	17	23	55	53	93	42	116	118	121	35	98	43	44	57	63
Operating lease right-of-use assets
332	398	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Finance lease right-of-use assets
22	24	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Intangible assets, net
16,039	16,525	17,011	17,497	17,983	18,469	18,955	19,441	19,927	20,413	-	-	-	-	-	-	-	-	-	-	-	-	-
Goodwill
-	-	-	-	-	-	-	-	-	-	-	-	718	-	718	718	718	-	718	-	-	0	-
Other intangible assets, net
-	-	-	-	-	-	-	-	-	-	19,353	19,884	21,128	-	842	867	892	-	946	-	-	0	-
Other long-term assets
59	59	59	-	-	-	-	126	126	126	126	126	126	125	126	76	76	76	-	-	-	0	-
Long-term assets held for sale
-	-	-	-	-	-	453	453	453	466	458	0	-	1,596	-	-	-	1,685	-	-	-	-	-
Patent
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	562	-	-	-
Total assets
32,113	38,172	28,725	34,134	38,867	43,151	30,835	33,344	36,331	39,022	26,382	30,381	33,865	5,564	8,309	5,535	9,390	8,201	7,288	8,770	10,067	8,395	1,586
Liabilities and stockholders’ equity
Current liabilities
Accounts payable
3,480	1,995	1,735	1,740	1,258	934	1,245	981	1,133	633	642	1,029	935	410	862	957	1,262	495	953	989	621	986	57
Accrued compensation
338	283	-	-	-	274	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued clinical trial site costs
2,846	1,999	-	-	-	320	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating lease liabilities
315	305	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other current liabilities
308	382	-	-	-	349	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued compensation and other current liabilities
-	-	1,719	1,115	992	-	1,153	862	721	973	976	879	1,237	1,050	915	944	1,317	515	1,224	1,223	438	201	128
Current liabilities held for sale
-	-	-	-	-	-	110	102	88	127	113	214	-	246	-	-	-	1,316	-	-	-	-	-
Line of credit and accrued interest
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	101	-
Convertible promissory notes and accrued interest
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	13,991
Total current liabilities
7,287	4,964	3,454	2,855	2,250	1,877	2,508	1,945	1,942	1,733	1,731	2,122	2,172	1,707	1,777	1,901	2,579	3,192	6,028	13,349	1,059	1,289	14,178
Common Stock Issuable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	112	-	-	-
Series B warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,851	11,025	-	-	-
Long-term liabilities
Warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,464
Contingent liability for Essentialis purchase price
6,522	5,938	6,066	6,038	5,855	5,649	5,671	5,443	-	5,082	-	-	-	-	-	-	-	-	-	-	-	-	-
Contingent liability for Essentialis purchase price
-	-	-	-	-	-	-	-	5,510	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other long-term liabilities
60	147	38	-	-	-	-	13	13	13	1,132	1,132	1,201	61	196	200	200	-	151	-	-	0	-
Long-term liabilities held for sale
-	-	-	-	-	-	1,750	1,050	625	225	0	0	-	81	-	-	-	109	-	-	-	-	-
Total long-term liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,551	3,053	20,311	-	-
Total liabilities
22,632	23,225	13,840	20,291	15,236	12,738	16,630	17,507	13,312	12,205	3,172	3,693	3,721	2,129	-	-	-	4,977	8,579	16,402	21,370	-	-
Commitments and contingencies (Note 6)
-	-	-	-	-	-	0	0	0	-	0	0	0	0	0	0	0	0	-	-	-	0	0
Commitments and contingencies
-	-	-	-	-	-	0	0	0	-	0	0	0	0	0	0	0	0	-	-	-	0	0
Preferred stock
-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Common stock
45	45	32	32	32	32	21	21	20	19	10	48	47	3	15	15	15	2	12	8	7	6	0
Additional paid-in-capital
173,100	172,708	158,034	157,881	157,661	157,413	141,479	141,187	140,733	140,495	132,154	131,807	131,296	101,743	101,395	95,543	95,255	89,467	82,099	72,469	70,679	59,141	19,235
Accumulated deficit
-163,664	-157,806	-143,181	-144,070	-134,062	-127,032	-127,295	-125,371	-117,734	-113,697	-108,954	-105,167	-101,199	-98,311	-95,698	-92,948	-89,436	-86,246	-83,402	-80,109	-81,989	-70,338	-57,100
Total stockholders’ equity
9,481	14,947	14,885	13,843	23,631	30,413	14,205	15,837	23,019	26,817	23,210	26,688	30,144	3,435	5,712	2,610	5,834	3,223	-1,291	-7,632	-11,303	-11,189	-37,864
Total liabilities and stockholders’ equity
32,113	38,172	28,725	34,134	38,867	43,151	30,835	33,344	36,331	39,022	26,382	30,381	33,865	5,564	8,309	5,535	9,390	8,201	7,288	8,770	10,067	8,395	1,586
Series A Warrant Liability [Member]
Warrant liability
-	-	25	51	73	49	-	-	-	70	-	-	-	-	-	-	-	-	-	-	-	-	-
Series C Warrant [Member]
Warrant liability
-	-	-	-	-	-	-	-	-	6	-	-	-	-	-	-	-	-	-	-	-	-	-
2017 PIPE Warrant Liability [Member]
Warrant liability
7,656	10,822	3,667	10,202	6,274	4,563	-	-	-	5,076	-	-	-	-	-	-	-	-	-	-	-	-	-
2018 PIPE Warrant Liability [Member]
Warrant liability
1,107	1,354	590	1,145	784	600	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-